Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Policy

U. of Minnesota sues Gilead

School says drugmaker’s hepatitis C compound sofosbuvir infringes its patent

by Marc S. Reisch
September 1, 2016 | A version of this story appeared in Volume 94, Issue 35

The University of Minnesota filed a complaint in federal court on Aug. 29 charging that Gilead Sciences’ multi-billion-dollar hepatitis C drugs Sovaldi, Harvoni, and Epclusa infringe on a two-year-old patent the university owns.

[+]Enlarge
The university says its patent covers Gilead’s sofosbuvir. Its complaint states that R1 (above) can be uracil, R2 is a halogen, R3 is a hydroxyl, R4 can by aryl, R5 is an amino acid, R6 and R7 are H or C1 to C6 alkyl, and X can be oxygen.
Two chemical structures.
The university says its patent covers Gilead’s sofosbuvir. Its complaint states that R1 (above) can be uracil, R2 is a halogen, R3 is a hydroxyl, R4 can by aryl, R5 is an amino acid, R6 and R7 are H or C1 to C6 alkyl, and X can be oxygen.

Each of the hepatitis C drugs contains sofosbuvir, an antiviral agent that the university claims is covered by a patent awarded to Carston R. Wagner, a medicinal chemistry professor in the school’s College of Pharmacy. Wagner is also executive editor of the ACS journal Molecular Pharmaceutics. ACS is the publisher of C&EN.

Despite meeting with the university a year ago concerning the claim, Gilead “has continued its infringing conduct,” the complaint says. The university is seeking unspecified compensatory damages and royalties to be determined in a jury trial.

In a statement, Gilead contends that the university “did not invent sofosbuvir, nor did they contribute to its development. We believe their patent to be invalid and not infringed by the sale of Gilead’s medicines for chronic hepatitis C.”

The university’s patent, US 8815830, was issued in August 2014 and builds on Wagner patents going back a decade. Called “Nucleosides with Antiviral and Anticancer Activity,” it is the result of Wagner’s research into the role of human histidine triad nucleotide-binding protein 1 (hHint1), according to the complaint.

That work led Wagner to develop a family of compounds that act as antiviral agents against the hepatitis C virus, the complaint says. “Gilead’s sofosbuvir medicines incorporate these contributions of Dr. Wagner,” notes the complaint.

The university’s case against Gilead is not the first time intellectual property rights to sofosbuvir have been disputed. In March, a federal jury in California ordered Gilead to pay Merck & Co. $200 million for infringing on a patent that Merck says led to the development of sofosbuvir. However, a federal judge recently overturned the suit.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.